MINI FUTURE LONG - MODERNA | Delayed Deutsche Boerse AG 10:50:39 19/06/2024 BST | ||
| 7.5 EUR | -2.98% |
|
| Current month | -9.06% | ||
| 1 month | +2.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 7.5 | -2.98% |
| 18/06/24 | 7.73 | -5.15% |
| 17/06/24 | 8.15 | -2.04% |
| 14/06/24 | 8.32 | -5.02% |
| 13/06/24 | 8.76 | -1.79% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 10:50 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PN0QRX |
| ISIN | DE000PN0QRX7 |
| Date issued | 28/05/2020 |
| Strike | 51.26 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.65 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 39.59 € |
|---|---|
| Lowest since issue | 1.23 € |
| Spread | 0.12 € |
| Spread % | 1.57% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Certificates
- Certificat